CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: EIF2S3 (ImmuneEditome ID:1968)

1. Gene summary of enriched editing regions for EIF2S3

check button Gene summary
Gene informationGene symbol

EIF2S3

Gene ID

1968

GeneSynonymsEIF2|EIF2G|EIF2gamma|MEHMO|MRXSBRK|eIF-2gA
GeneCytomap

Xp22.11

GeneTypeprotein-coding
GeneDescriptioneukaryotic translation initiation factor 2 subunit 3|eIF-2-gamma X|eIF-2gX|eukaryotic translation initiation factor 2 subunit gamma X|eukaryotic translation initiation factor 2, subunit 3 gamma, 52kDa|eukaryotic translation initiation factor 2G|mental retardation, epileptic seizures, hypogonadism and -genitalism, microcephaly and obesity syndrome
GeneModificationdate20230409
UniprotIDP41091
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chrX:24075077-24077252:+ENST00000253039.7ENSG00000130741.9EIF2S3exonic(T)n,AluJr,L1MC4,AluSx,AluSz,(TTTCAT)nchrX:24075077-24077252:+.alignment


Top

2. Tumor-specific enriched editing regions for EIF2S3


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chrX:24075077-24077252:+LUSCEER9.7271e-05image
ENSG00000130741.9,EIF2S3LUSCEAG1.0207e-04image
chrX:24075077-24077252:+PRADEER3.5150e-02image
ENSG00000130741.9,EIF2S3PRADEAG3.7220e-02image
ENSG00000130741.9,EIF2S3THCAEAG3.7719e-04image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000130741.9,EIF2S3BLCAPathEAG3.7571e-021.7412e-020.1609image
ENSG00000130741.9,EIF2S3THCAPathEAG1.9223e-038.4952e-040.1812image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for EIF2S3


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chrX:24075077-24077252:+ESCAEERENSG00000171621,SPSB10.38561.5475e-037.1430e-070.4006imageNCNBP;CSTF2T;DDX54;DGCR8;EIF4A3;EIF4G2;ELAVL1;FBL;FMR1;FUS;HNRNPA1;HNRNPC;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;LARP7;LIN28;LIN28A;MOV10;NOP56;NOP58;PRPF8;PTBP1;RBFOX2;RBM10;RC3H1;SND1;SRSF1;SRSF7;TAF15;TARDBP;U2AF2;UPF1;ZNF184NADendritic_cells_restingGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION
chrX:24075077-24077252:+PCPGEERENSG00000187653,TMSB4XP8-0.36471.1810e-033.6956e-07-0.4086imageNNNAGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION

More results



Top

4. Enriched editing regions and immune related splicing for EIF2S3


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000130741.9,EIF2S3
ESCAEAGESENSG00000111450.9chr12130790833:130791977:130795994:130796120:130798524:130798635-0.31134.6423e-022.6705e-06-0.4104imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G1;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZC3H7B;ZNF184STX2Dendritic_cells_restingGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION
ENSG00000130741.9,EIF2S3
ESCAEAGIRENSG00000140416.15chr1563062575:63064142:63065895:63066003-0.30581.7161e-027.3484e-07-0.4479imageNACIN1;ADAR;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RBM6;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZFP36;ZNF184TPM1B_cells_naiveGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION
chrX:24075077-24077252:+
ESCAEERESENSG00000100813.10chr1423065965:23066008:23067313:23068671:23069475:230695250.34973.4138e-026.2453e-080.4338imageNACIN1;AIFM1;ALYREF;BUD13;CAPRIN1;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DICER1;EIF4A3;EIF4G2;ELAVL1;FBL;FMR1;FUS;FXR2;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;MOV10;MSI2;NOP56;NOP58;PRPF8;PTBP1;RBFOX2;RBM10;RBM22;RBM47;RBM5;RC3H1;RNF219;SAFB2;SBDS;SF3A3;SLBP;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TRA2A;U2AF2;UPF1;ZNF184ACIN1T_cells_CD4_memory_activatedGSVA_HALLMARK_PEROXISOME
chrX:24075077-24077252:+
ESCAEERESENSG00000111450.9chr12130790833:130791977:130795994:130796120:130798524:130798635-0.31743.5120e-022.2474e-06-0.4164imageNACIN1;AIFM1;ALYREF;BUD13;CNBP;CSTF2T;DDX3X;DGCR8;DICER1;EIF4A3;EIF4G2;ELAVL1;FBL;FMR1;FUS;FXR2;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;KHDRBS3;KHSRP;LARP7;LIN28;LIN28A;LIN28B;MOV10;MSI2;NOP56;NOP58;PRPF8;PTBP1;RBFOX2;RBM10;RBM22;RBM47;RBM5;RNF219;SAFB2;SF3A3;SLBP;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TRA2A;U2AF2;UPF1;ZNF184STX2Dendritic_cells_restingGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION
chrX:24075077-24077252:+
ESCAEERIRENSG00000014914.15chr1149936153:149936229:149936581:149936834-0.31642.4557e-024.8080e-06-0.4135imageNBUD13;CSTF2T;DDX54;DGCR8;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPA1;HNRNPC;HNRNPU;IGF2BP2;KHSRP;NOP58;PRPF8;PTBP1;RBFOX2;RBM10;RBM47;SMNDC1;SRSF1;TAF15;TARDBP;U2AF2;UPF1;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_MYOGENESIS
ENSG00000130741.9,EIF2S3
ESCAEAGESENSG00000100813.10chr1423065965:23066008:23067313:23068671:23069475:230695250.35343.2947e-021.1230e-070.4234imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G1;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RC3H1;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZFP36;ZNF184ACIN1T_cells_CD4_memory_activatedGSVA_HALLMARK_PEROXISOME
chrX:24075077-24077252:+
ESCAEERA3ENSG00000100813.10chr1423069475:23069525:23064354:23066008:23064354:23068671-0.36042.5339e-023.9328e-08-0.4397imageNACIN1;AIFM1;ALYREF;BUD13;CAPRIN1;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DICER1;EIF4A3;EIF4G2;ELAVL1;FBL;FMR1;FUS;FXR2;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;MOV10;MSI2;NOP56;NOP58;PRPF8;PTBP1;RBFOX2;RBM10;RBM22;RBM47;RBM5;RC3H1;RNF219;SAFB2;SBDS;SF3A3;SLBP;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TRA2A;U2AF2;UPF1;ZNF184ACIN1T_cells_CD4_memory_activatedGSVA_HALLMARK_PEROXISOME
chrX:24075077-24077252:+
ESCAEERIRENSG00000140416.15chr1563062575:63064142:63065895:63066003-0.31839.6169e-033.0509e-07-0.4652imageNACIN1;BUD13;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DICER1;EIF4A3;EIF4G2;ELAVL1;FBL;FMR1;FUS;FXR2;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;MOV10;MSI2;NOP56;NOP58;PRPF8;PTBP1;RBFOX2;RBM10;RBM22;RBM47;RBM5;RNF219;SAFB2;SF3A3;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TRA2A;U2AF2;UPF1;ZNF184TPM1B_cells_naiveGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION
ENSG00000130741.9,EIF2S3
ESCAEAGIRENSG00000014914.15chr1149936153:149936229:149936581:149936834-0.30234.3191e-026.3252e-06-0.4055imageNADAR;BUD13;CELF2;CSTF2T;DDX54;DGCR8;EIF4A3;ELAVL1;FBL;FMR1;FUS;HNRNPA1;HNRNPC;HNRNPK;HNRNPU;IGF2BP2;KHDRBS1;KHSRP;NOP58;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;RBM47;SF3B4;SMNDC1;SRSF1;SRSF3;TAF15;TARDBP;TIAL1;U2AF1;U2AF2;UPF1;YTHDF1;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_MYOGENESIS
ENSG00000130741.9,EIF2S3
ESCAEAGA3ENSG00000100813.10chr1423069475:23069525:23064354:23066008:23064354:23068671-0.36352.4725e-027.5552e-08-0.4285imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G1;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RC3H1;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZFP36;ZNF184ACIN1T_cells_CD4_memory_activatedGSVA_HALLMARK_PEROXISOME

More results



Top

5. Enriched editing regions and immune infiltration for EIF2S3


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chrX:24075077-24077252:+ACCEERMast_cells_resting3.2701e-030.4485image
ENSG00000130741.9,EIF2S3ACCEAGMast_cells_resting3.2701e-030.4485image
ENSG00000130741.9,EIF2S3BLCAEAGMacrophages_M12.7934e-030.2016image
chrX:24075077-24077252:+CESCEERT_cells_CD4_memory_resting2.3336e-02-0.1595image
ENSG00000130741.9,EIF2S3CESCEAGT_cells_CD4_memory_resting2.2717e-02-0.1591image
ENSG00000130741.9,EIF2S3CHOLEAGT_cells_follicular_helper9.1080e-030.4757image
ENSG00000130741.9,EIF2S3COADEAGMast_cells_resting3.2368e-030.2208image
chrX:24075077-24077252:+ESCAEERB_cells_naive1.3288e-02-0.2066image
ENSG00000130741.9,EIF2S3ESCAEAGMast_cells_resting1.6695e-020.1985image
ENSG00000130741.9,EIF2S3GBMEAGMacrophages_M01.7090e-02-0.1945image
ENSG00000130741.9,EIF2S3HNSCEAGMacrophages_M29.3794e-030.1856image
ENSG00000130741.9,EIF2S3KICHEAGNK_cells_activated6.7682e-03-0.4690image
ENSG00000130741.9,EIF2S3KIRPEAGNK_cells_activated1.9290e-02-0.1948image
ENSG00000130741.9,EIF2S3LAMLEAGPlasma_cells1.3340e-020.2094image
chrX:24075077-24077252:+LGGEERT_cells_CD4_memory_resting7.8891e-03-0.1198image
ENSG00000130741.9,EIF2S3LGGEAGT_cells_CD4_memory_resting7.8186e-03-0.1199image
ENSG00000130741.9,EIF2S3LIHCEAGPlasma_cells4.8700e-030.2222image
chrX:24075077-24077252:+LUADEERT_cells_CD81.3258e-020.1266image
ENSG00000130741.9,EIF2S3LUADEAGT_cells_CD81.3258e-020.1266image
chrX:24075077-24077252:+LUSCEERMacrophages_M11.4283e-020.1250image
ENSG00000130741.9,EIF2S3LUSCEAGMacrophages_M11.5061e-020.1238image
chrX:24075077-24077252:+PRADEERMacrophages_M24.7526e-040.2005image
ENSG00000130741.9,EIF2S3PRADEAGMacrophages_M21.1837e-030.1854image
ENSG00000130741.9,EIF2S3READEAGT_cells_CD4_memory_activated1.0254e-02-0.3404image
ENSG00000130741.9,EIF2S3SKCMEAGT_cells_CD88.9995e-030.1542image
chrX:24075077-24077252:+STADEERT_cells_CD81.5189e-030.1752image
ENSG00000130741.9,EIF2S3STADEAGT_cells_CD81.9305e-030.1706image
ENSG00000130741.9,EIF2S3TGCTEAGB_cells_memory1.0313e-020.2470image
ENSG00000130741.9,EIF2S3THCAEAGT_cells_regulatory_(Tregs)3.6759e-030.1576image
ENSG00000130741.9,EIF2S3THYMEAGMast_cells_resting5.6123e-030.3033image
chrX:24075077-24077252:+UCECEERT_cells_gamma_delta1.3602e-040.3894image
ENSG00000130741.9,EIF2S3UCECEAGT_cells_gamma_delta3.3938e-040.3637image
ENSG00000130741.9,EIF2S3UCSEAGMast_cells_activated6.0633e-040.5580image


Top

6. Enriched editing regions and immune gene sets for EIF2S3


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
ENSG00000130741.9,EIF2S3LUSCEAG4.9247e-02image1.0226e-030.1668image
chrX:24075077-24077252:+STADEER6.5258e-03image2.6808e-030.1660image
ENSG00000130741.9,EIF2S3STADEAG1.2530e-02image6.2833e-030.1506image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000130741.9,EIF2S3ACCGSVA_HALLMARK_GLYCOLYSISEAG4.5043e-020.3147image
chrX:24075077-24077252:+ACCGSVA_HALLMARK_GLYCOLYSISEER4.5043e-020.3147image
ENSG00000130741.9,EIF2S3BLCAGSVA_HALLMARK_KRAS_SIGNALING_UPEAG3.4004e-050.2768image
chrX:24075077-24077252:+BRCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER8.0852e-110.2128image
ENSG00000130741.9,EIF2S3BRCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.6858e-100.2092image
ENSG00000130741.9,EIF2S3CESCGSVA_HALLMARK_MITOTIC_SPINDLEEAG3.5473e-04-0.2471image
chrX:24075077-24077252:+CESCGSVA_HALLMARK_MITOTIC_SPINDLEEER2.3952e-03-0.2125image
ENSG00000130741.9,EIF2S3CHOLGSVA_HALLMARK_P53_PATHWAYEAG3.8956e-03-0.5192image
ENSG00000130741.9,EIF2S3COADGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG3.3559e-020.1603image
ENSG00000130741.9,EIF2S3DLBCGSVA_HALLMARK_KRAS_SIGNALING_DNEAG3.2987e-030.5358image
ENSG00000130741.9,EIF2S3ESCAGSVA_HALLMARK_MYOGENESISEAG2.7770e-040.2976image
chrX:24075077-24077252:+ESCAGSVA_HALLMARK_MYOGENESISEER1.4013e-040.3131image
ENSG00000130741.9,EIF2S3GBMGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG2.4705e-030.2454image
ENSG00000130741.9,EIF2S3HNSCGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG2.2352e-060.3313image
ENSG00000130741.9,EIF2S3KICHGSVA_HALLMARK_P53_PATHWAYEAG2.6429e-030.5136image
ENSG00000130741.9,EIF2S3KIRCGSVA_HALLMARK_COAGULATIONEAG3.1405e-170.4860image
chrX:24075077-24077252:+KIRCGSVA_HALLMARK_COAGULATIONEER3.2245e-170.4858image
ENSG00000130741.9,EIF2S3KIRPGSVA_HALLMARK_HYPOXIAEAG1.0747e-030.2698image
ENSG00000130741.9,EIF2S3LAMLGSVA_HALLMARK_KRAS_SIGNALING_DNEAG9.9976e-030.2178image
chrX:24075077-24077252:+LGGGSVA_HALLMARK_BILE_ACID_METABOLISMEER5.3441e-100.2755image
ENSG00000130741.9,EIF2S3LGGGSVA_HALLMARK_BILE_ACID_METABOLISMEAG5.6217e-100.2751image
ENSG00000130741.9,EIF2S3LIHCGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG3.1178e-03-0.2330image
chrX:24075077-24077252:+LUADGSVA_HALLMARK_HEME_METABOLISMEER1.6043e-040.1919image
ENSG00000130741.9,EIF2S3LUADGSVA_HALLMARK_HEME_METABOLISMEAG1.6043e-040.1919image
chrX:24075077-24077252:+LUSCGSVA_HALLMARK_COMPLEMENTEER1.5031e-070.2641image
ENSG00000130741.9,EIF2S3LUSCGSVA_HALLMARK_COMPLEMENTEAG2.5222e-070.2591image
ENSG00000130741.9,EIF2S3MESOGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.7883e-030.4268image
chrX:24075077-24077252:+MESOGSVA_HALLMARK_PANCREAS_BETA_CELLSEER1.7883e-030.4268image
ENSG00000130741.9,EIF2S3OVGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.2533e-040.2598image
chrX:24075077-24077252:+OVGSVA_HALLMARK_PANCREAS_BETA_CELLSEER2.8842e-050.2830image
chrX:24075077-24077252:+PAADGSVA_HALLMARK_MYOGENESISEER1.3248e-050.3431image
ENSG00000130741.9,EIF2S3PAADGSVA_HALLMARK_MYOGENESISEAG1.3215e-050.3431image
chrX:24075077-24077252:+PCPGGSVA_HALLMARK_PROTEIN_SECRETIONEER2.7660e-030.2476image
ENSG00000130741.9,EIF2S3PCPGGSVA_HALLMARK_PROTEIN_SECRETIONEAG2.7428e-030.2478image
ENSG00000130741.9,EIF2S3PRADGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG7.8079e-060.2536image
chrX:24075077-24077252:+PRADGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER4.3192e-060.2618image
ENSG00000130741.9,EIF2S3READGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.8575e-020.3136image
ENSG00000130741.9,EIF2S3SARCGSVA_HALLMARK_HYPOXIAEAG6.0080e-040.2583image
chrX:24075077-24077252:+SARCGSVA_HALLMARK_HYPOXIAEER6.0080e-040.2583image
ENSG00000130741.9,EIF2S3SKCMGSVA_HALLMARK_APOPTOSISEAG2.0577e-080.3240image
ENSG00000130741.9,EIF2S3STADGSVA_HALLMARK_KRAS_SIGNALING_DNEAG3.4094e-050.2267image
chrX:24075077-24077252:+STADGSVA_HALLMARK_KRAS_SIGNALING_DNEER5.2811e-060.2495image
ENSG00000130741.9,EIF2S3TGCTGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG3.5740e-03-0.2793image
ENSG00000130741.9,EIF2S3THCAGSVA_HALLMARK_GLYCOLYSISEAG1.8131e-140.4007image
ENSG00000130741.9,EIF2S3THYMGSVA_HALLMARK_MITOTIC_SPINDLEEAG3.6424e-06-0.4862image
chrX:24075077-24077252:+UCECGSVA_HALLMARK_MITOTIC_SPINDLEEER1.7823e-02-0.2479image
ENSG00000130741.9,EIF2S3UCECGSVA_HALLMARK_MITOTIC_SPINDLEEAG8.3513e-03-0.2720image
ENSG00000130741.9,EIF2S3UCSGSVA_HALLMARK_HYPOXIAEAG4.0160e-020.3537image


Top

7. Enriched editing regions and drugs for EIF2S3


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000130741.9,EIF2S3BLCACGP.082996EAG6.9719e-06-0.2991image
ENSG00000130741.9,EIF2S3BRCAABT.263EAG1.5097e-040.1253image
chrX:24075077-24077252:+BRCAABT.263EER9.4027e-050.1291image
chrX:24075077-24077252:+CESCGNF.2EER1.4607e-04-0.2641image
ENSG00000130741.9,EIF2S3CESCGNF.2EAG1.0433e-06-0.3333image
ENSG00000130741.9,EIF2S3CHOLBAY.61.3606EAG3.8454e-03-0.5199image
ENSG00000130741.9,EIF2S3COADAICAREAG5.9246e-05-0.2979image
ENSG00000130741.9,EIF2S3DLBCElesclomolEAG1.7832e-03-0.5638image
ENSG00000130741.9,EIF2S3ESCAGNF.2EAG7.9504e-05-0.3217image
chrX:24075077-24077252:+ESCACGP.60474EER3.2420e-05-0.3401image
ENSG00000130741.9,EIF2S3GBMIPA.3EAG5.5380e-050.3230image
ENSG00000130741.9,EIF2S3HNSCGSK.650394EAG5.3149e-050.2852image
ENSG00000130741.9,EIF2S3KICHAZD6482EAG5.9557e-03-0.4755image
chrX:24075077-24077252:+KIRCAZD.0530EER1.0016e-10-0.3824image
ENSG00000130741.9,EIF2S3KIRCAZD.0530EAG9.2556e-11-0.3831image
ENSG00000130741.9,EIF2S3KIRPA.770041EAG1.1882e-03-0.2675image
ENSG00000130741.9,EIF2S3LAMLBIBW2992EAG2.7021e-020.1876image
chrX:24075077-24077252:+LGGGSK.650394EER7.5990e-110.2882image
ENSG00000130741.9,EIF2S3LGGGSK.650394EAG7.9060e-110.2879image
ENSG00000130741.9,EIF2S3LIHCAICAREAG2.4425e-03-0.2387image
chrX:24075077-24077252:+LUADCytarabineEER6.6947e-030.1385image
ENSG00000130741.9,EIF2S3LUADCytarabineEAG6.6947e-030.1385image
chrX:24075077-24077252:+LUSCBMS.536924EER6.0699e-08-0.2721image
ENSG00000130741.9,EIF2S3LUSCBMS.536924EAG1.0803e-07-0.2667image
ENSG00000130741.9,EIF2S3MESOGefitinibEAG1.2363e-030.4399image
chrX:24075077-24077252:+MESOGefitinibEER1.2363e-030.4399image
chrX:24075077-24077252:+OVBAY.61.3606EER2.7964e-050.2835image
ENSG00000130741.9,EIF2S3OVBAY.61.3606EAG4.2110e-050.2768image
ENSG00000130741.9,EIF2S3PAADJNJ.26854165EAG3.2159e-03-0.2360image
chrX:24075077-24077252:+PAADJNJ.26854165EER3.2143e-03-0.2360image
chrX:24075077-24077252:+PCPGCamptothecinEER3.4111e-030.2425image
ENSG00000130741.9,EIF2S3PCPGCamptothecinEAG3.3755e-030.2427image
ENSG00000130741.9,EIF2S3PRADEtoposideEAG2.6432e-060.2660image
chrX:24075077-24077252:+PRADEtoposideEER3.2416e-060.2650image
ENSG00000130741.9,EIF2S3READBIRB.0796EAG4.0025e-030.3787image
chrX:24075077-24077252:+SARCCEP.701EER1.5233e-04-0.2840image
ENSG00000130741.9,EIF2S3SARCCEP.701EAG1.5233e-04-0.2840image
ENSG00000130741.9,EIF2S3SKCMDoxorubicinEAG4.6636e-070.2927image
chrX:24075077-24077252:+STADDasatinibEER7.1784e-07-0.2720image
ENSG00000130741.9,EIF2S3STADDasatinibEAG9.9604e-07-0.2674image
ENSG00000130741.9,EIF2S3TGCTAZ628EAG2.5565e-03-0.2888image
ENSG00000130741.9,EIF2S3THCAIPA.3EAG2.5918e-100.3351image
ENSG00000130741.9,EIF2S3THYMEtoposideEAG4.0958e-080.5614image
ENSG00000130741.9,EIF2S3UCECGDC.0449EAG7.4780e-03-0.2757image
chrX:24075077-24077252:+UCECGDC.0449EER2.1593e-02-0.2406image
ENSG00000130741.9,EIF2S3UCSCyclopamineEAG5.7683e-03-0.4635image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType